Filing Details
Arbutus Biopharma Corp (NASDAQ:ABUS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:ABUS
Arbutus Biopharma Corp (ABUS) Files Quarterly Report for Q0
Arbutus Biopharma Corp (NASDAQ:ABUS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
At publication ·
What changed
Arbutus Biopharma Corp (NASDAQ:ABUS) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Arbutus Biopharma Corp filed its quarterly report (Form 10-Q) with the SEC on August 12, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $4.59 with a market capitalization of $896.2 million as of the filing date.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last annual filing.
Market Context
Arbutus Biopharma Corp's stock currently trades at $4.59 with a market capitalization of $896.2M.
The 10-Q provides Arbutus Biopharma Corp's quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Arbutus Biopharma Corp are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ABUS Stock Page
Frequently Asked Questions
Where can I read ABUS's SEC filings?
Browse all filings on our ABUS SEC filings page.
What types of SEC filings does Arbutus Biopharma Corp file?
Public companies like Arbutus Biopharma Corp file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.